CIK 0000875045 · Large accelerated filer
BIOGEN INC.
Sign in to watch- Ticker
- BIIB
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 330112644
- Phone
- 6176792000
- Business address
- 225 BINNEY STREET, CAMBRIDGE, MA, 02142
- Former names
- BIOGEN IDEC INC., BIOGEN IDEC INC, IDEC PHARMACEUTICALS CORP / DE, IDEC PHARMACEUTICALS CORP / CA
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-02-07 | Keeney Adam Head of Corporate Development | Grant or award · Restricted Stock Unit | +5,405 | 5,405 | ||
| 2024-02-07 | Kramer Robin Chief Accounting Officer | Grant or award · Restricted Stock Unit | +2,110 | 2,110 | ||
| 2024-02-07 | MCDONNELL MICHAEL R EVP, Chief Financial Officer | Grant or award · Restricted Stock Unit | +6,650 | 6,650 | ||
| 2024-02-07 | Murphy Nicole Head of Pharm Ops and Tech | Grant or award · Restricted Stock Unit | +5,820 | 5,820 | ||
| 2024-02-07 | Singhal Priya Head of Development | Grant or award · Restricted Stock Unit | +6,650 | 6,650 | ||
| 2024-02-07 | Viehbacher Christopher President and CEO | Grant or award · Restricted Stock Unit | +27,025 | 27,025 | ||
| 2024-02-02 | Singhal Priya Head of Development | Sale 10b5-1 | −634 | $245.93 | $156K | 4,097.09 |
| 2024-02-01 | Singhal Priya Head of Development | Option exercise 10b5-1 | +1,828 | 5,292.09 | ||
| 2024-02-01 | Singhal Priya Head of Development | Shares withheld for taxes 10b5-1 | −561 | $247.83 | $139K | 4,731.09 |
| 2024-02-01 | Singhal Priya Head of Development | Option exercise · Restricted Stock Unit 10b5-1 | −1,828 | 3,657 | ||
| 2024-01-29 | Singhal Priya Head of Development | Grant or award · Performance Stock Unit | +819 | 819 | ||
| 2024-01-29 | Murphy Nicole Head of Pharm Ops and Tech | Grant or award · Performance Stock Unit | +856 | 856 | ||
| 2024-01-29 | MCDONNELL MICHAEL R EVP, Chief Financial Officer | Grant or award · Performance Stock Unit | +4,568 | 4,568 | ||
| 2024-01-29 | Kramer Robin Chief Accounting Officer | Grant or award · Performance Stock Unit | +914 | 914 | ||
| 2024-01-29 | Izzar Rachid Head of Global Product Strat. | Grant or award · Performance Stock Unit | +1,370 | 1,370 | ||
| 2024-01-29 | Gregory Ginger EVP, Human Resources | Grant or award · Performance Stock Unit | +3,197 | 3,197 | ||
| 2024-01-29 | ALEXANDER SUSAN H EVP Chief Legal Officer | Grant or award · Performance Stock Unit | +3,423 | 3,423 | ||
| 2023-12-11 | Singhal Priya Head of Development | Sale 10b5-1 | −110 | $248.00 | $27K | 3,464.09 |
| 2023-12-08 | Singhal Priya Head of Development | Option exercise 10b5-1 | +426 | 3,780.09 | ||
| 2023-12-08 | Singhal Priya Head of Development | Shares withheld for taxes 10b5-1 | −206 | $239.29 | $49K | 3,574.09 |
Page 19 of 29 · 579 trades